| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
5'-O-DMT-2'-O-iBu-N-Bz-Guanosine does not have a specific biological target as it is a synthetic building block for oligonucleotide synthesis. Its role is to serve as a protected guanosine monomer for the synthesis of RNA oligonucleotides. The protecting groups are designed to be selectively removed during the synthesis process to allow for the formation of phosphodiester bonds between nucleotides.
|
|---|---|
| ln Vitro |
In vitro activity is not applicable to 5'-O-DMT-2'-O-iBu-N-Bz-Guanosine as it is a synthetic intermediate. Its utility is demonstrated in its ability to be incorporated into RNA oligonucleotides through solid-phase synthesis. The compound's purity ensures high-quality oligonucleotide synthesis for molecular biology applications.
|
| ln Vivo |
In vivo activity is not applicable to 5'-O-DMT-2'-O-iBu-N-Bz-Guanosine as it is a chemical reagent for research use only, not a therapeutic agent. The compound is not intended for administration to living organisms.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not performed for 5'-O-DMT-2'-O-iBu-N-Bz-Guanosine, as it is a synthetic intermediate. Its characterization typically involves chemical analysis methods such as HPLC, NMR, and mass spectrometry to confirm identity and purity.
|
| Cell Assay |
In vitro cellular assays are not applicable to 5'-O-DMT-2'-O-iBu-N-Bz-Guanosine. The compound is used exclusively in chemical synthesis reactions for the production of RNA oligonucleotides, which can subsequently be used in cellular assays. The compound itself is not tested directly on cells.
|
| Animal Protocol |
In vivo animal experiments are not applicable to 5'-O-DMT-2'-O-iBu-N-Bz-Guanosine. The compound is a research chemical used in oligonucleotide synthesis and is not intended for in vivo administration.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable to 5'-O-DMT-2'-O-iBu-N-Bz-Guanosine as it is a synthetic intermediate, not a therapeutic agent. The compound has a molecular weight of 769.96 and a molecular formula of C41H51N5O8Si. LogP is 6.874 and PSA is 159.31. Density is 1.25 g/cm3. It is not intended for systemic administration.
|
| Toxicity/Toxicokinetics |
Toxicological data for 5'-O-DMT-2'-O-iBu-N-Bz-Guanosine are not applicable as it is a research chemical. The compound is intended for research use only and is not for human therapeutic application. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
5'-O-DMT-2'-O-iBu-N-Bz-Guanosine (5'-O-DMT-2'-O-TBDMS-ibu-rG) (CAS#: 81279-39-2) has the molecular formula C41H51N5O8Si and a molecular weight of 769.96. It is a modified ribonucleoside derivative used in solid-phase RNA synthesis. The compound can be used for silyl protection of ribonucleosides. It is for research use only.
|
| Molecular Formula |
C41H51N5O8SI
|
|---|---|
| Molecular Weight |
769.96
|
| Exact Mass |
769.351
|
| CAS # |
81279-39-2
|
| PubChem CID |
135451092
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.25
|
| LogP |
6.874
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
55
|
| Complexity |
1310
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(C)C(=O)NC1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COC(C4=CC=CC=C4)(C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC)O)O[Si](C)(C)C(C)(C)C
|
| InChi Key |
JMCNKJFOIJGYRG-CJEGOSRCSA-N
|
| InChi Code |
InChI=1S/C41H51N5O8Si/c1-25(2)36(48)44-39-43-35-32(37(49)45-39)42-24-46(35)38-34(54-55(8,9)40(3,4)5)33(47)31(53-38)23-52-41(26-13-11-10-12-14-26,27-15-19-29(50-6)20-16-27)28-17-21-30(51-7)22-18-28/h10-22,24-25,31,33-34,38,47H,23H2,1-9H3,(H2,43,44,45,48,49)/t31-,33-,34-,38-/m1/s1
|
| Chemical Name |
N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-[tert-butyl(dimethyl)silyl]oxy-4-hydroxyoxolan-2-yl]-6-oxo-1H-purin-2-yl]-2-methylpropanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (129.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.25 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2988 mL | 6.4938 mL | 12.9877 mL | |
| 5 mM | 0.2598 mL | 1.2988 mL | 2.5975 mL | |
| 10 mM | 0.1299 mL | 0.6494 mL | 1.2988 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
